Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 2/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.64 |
| ▸ | SNCA | P37840 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600419 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL42712 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL3275185 | 0.87 | CYP19A1 (0.78) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7097095 | 0.87 | CYP19A1 (0.78) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL6821320 | 0.87 | CYP19A1 (0.78) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL349057 | 0.86 | CYP19A1 (0.76) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL349056 | 0.86 | CYP19A1 (0.76) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL10187417 | 0.86 | CYP19A1 (0.76) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7649810 | 0.86 | CYP19A1 (0.75) | CYP19A1 | |
| SCHEMBL10528769 | 0.84 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| US-12116638-B2 | Estrogen receptor mutations and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2024-10-15 | — | — | US | claimed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024039860-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| WO-2024039861-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| WO-2024039858-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| US-20220251667-A1 | NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-11 | — | — | US | claimed |
| EP-3912680-A1 | TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| US-20210322386-A1 | METHODS OF DELAYING AND REVERSING ALZHEIMER'S DISEASE PROGRESSION | LOMA LINDA UNIVERSITY (US) | 2021-10-21 | — | — | US | claimed |
| WO-2008127605-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CALCITONIN AND AN AROMATASE INHIBITOR | MEDITRINA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| WO-2008042508-A1 | GRP78 AS A PREDICTOR OF RESPONSIVENESS TO THERAPEUTIC AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-04-10 | — | — | WO | claimed |
| US-20050059646-A1 | Use of 4-androstene-3,6,17-trione to elevate testosterone levels and the testosterone/estrogen ratio in males | PROVIANT TECHNOLOGY INC. (US) | 2005-03-17 | — | — | US | claimed |
| US-20050049231-A1 | Local delivery of aromatase inhibitor using intravaginal device; estrogen dependent proliferative disorders of uterus; minimal side effects, longer term treatment, variable dosage | ARES TRADING, S.A. (CH) | 2005-03-03 | — | — | US | claimed |
| EP-1423165-A2 | INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS | Metris Therapeutics Limited (GB) | 2004-06-02 | — | — | EP | claimed |
| US-6696432-B1 | SYNERGYSTIC MIXTURES OF PRASTERONE, PREFERENTIAL ENZYME INHIBITORS SUCH AS FORMESTANE, TESTOLACTONE OR VOROZOLE AND CARRIERS, ADMINISTERED FOR PROPHYLAXIS OF HYPOANDROGENISM | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | claimed |
| WO-2003015872-A2 | INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS | METRIS THERAPEUTICS LIMITED (GB) | 2003-02-27 | — | — | WO | claimed |
| US-5733902-A | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-31 | — | — | US | claimed |
| US-4598072-A | Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | claimed |
| US-4596797-A | Urogenital disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESRRA, GPER1, ESR2 | CYP19A1 12/4885ALDH1A1 1137/4885LMNA 3709/4885 |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | CYP19A1 2/4885ALDH1A1 1842/4885LMNA 2870/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | CYP19A1 2/4885ALDH1A1 1842/4885LMNA 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.